EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Preclinical Evidence for Phage Therapy to Treat Mycobacterial Infections: A Narrative Review

Saskia Janssen, Sasha E. Larsen, Carl Morrow, Bhavna Ramsubag, Marta Pozuelo Torres, Carlos A. Guerrero Bustamante, Rhea N. Coler, Jakko van Ingen, Graham F. Hatfull, Andreas H. Diacon

PHAGE: Therapy, Applications, and Research · 2025-09-01 · 6 (3) · 140-153

DOI: 10.1089/phage.2024.0059 ↗
AbstractBibliografische Angaben

Abstract

Phage therapy shows promise for treating mycobacterial infections, though clinical trial data on efficacy are still needed. We review preclinical studies assessing the efficacy and safety of phage therapy in mycobacterial diseases, focusing on in vitro , ex vivo , and in vivo models to inform clinical trial design. Most studies addressed Mycobacterium tuberculosis (M. tb) , with phage D29 commonly used. Of all studies reporting activity, 91% (20/22) reported reduced mycobacterial counts. Some phages (4/7 assessed) also demonstrated activity against intracellular mycobacteria. Animal models (seven studies) showed efficacy and safety of four phages assessed, in infection models for M. tb , Mycobacterium ulcerans , Mycobacterium avium , and Mycobacterium abscessus , respectively. Substantial variability in results could be explained by experimental designs used. To advance clinical trials, we recommend standardized preclinical experiments on phage susceptibility, intracellular activity, and sampling from infection sites. This preclinical evidence supports further exploration of phage therapy for mycobacterial infections in clinical trials.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →